About Alan Colowick
Alan Colowick is a director at Recode Therapeutics.
Form D filings also name Alan Colowick as a director at Alumis.
Alan Colowick reports to the SEC as a director or officer of 10 public companies, including Alumis (ALMS), Maze Therapeutics (MAZE) and Personalis (PSNL).
Alan Colowick first appears on SEC filings in 2006.
Experience
This experience comes from SEC filings. The years are when the filings name Alan Colowick in the role, so the role may have started earlier or lasted longer.
MI
Maze Therapeutics, Inc.
Director
2025 · Public company (MAZE)
PI
Personalis, Inc.
Director
2019 – 2023 · Public company (PSNL)
AI
Acelyrin, Inc.
Director
2023 · Public company (SLRN)
HI
Harpoon Therapeutics, Inc.
Director
2021 – 2023 · Public company (HARP)
PI
Principia Biopharma Inc.
Director
2018 – 2020 · Public company (PRNB)
DI
Dimension Therapeutics, Inc.
Director
2015 – 2017 · Public company (DMTX)
AI
Achaogen, Inc.
Director
2015 – 2017 · Public company (AKAO)
GC
Geron Corp.
President, Oncology
2006 – 2008 · Public company (GERN)
MI
Molecular Templates, Inc.
Chief Medical Officer
2006 · Public company (MTEM)
Key Colleagues at Startups
The people Alan Colowick works with at each company, as listed on that company's latest Form D.
Recode Therapeutics, Inc. · Form D, Oct 23, 2025
RH
Rana Al-Hallaq
Director
PM
Patricia Millican
Director
SS
Shehnaaz Suliman
Executive officer and director
EH
Edward Hurwitz
Director
DL
David Lockhart
Executive officer
DM
Dean Mitchell
Director
BZ
Basheer Zada
Director
IP
Inai Park
Director
HK
Helen Kim
Director
PT
Peter Thompson
Director
Rakhshita Dhar
Director
Alumis Inc. · Form D, Jul 24, 2024
SA
Srinivas Akkaraju
Director
JS
John Schroer
Executive officer
JT
James Tananbaum
Director
DR
Derrick Richardson
Executive officer
PM
Patrick Machado
Director
SS
Sapna Srivastava
Director
MB
Martin Babler
CEO and director
MB
Mark Bradley
Executive officer
ZY
Zhengbin Yao
Director
SK
Sara Klein
Executive officer
DG
David Goldstein
Executive officer
JD
Jorn Drappa
Executive officer
RH
Roy Hardiman
Executive officer